Joanna Filioti1, Kleomenis Spiroglou1, Emmanuel Roilides2. 1. 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, 54642, Thessaloniki, Greece. 2. 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, 54642, Thessaloniki, Greece. roilides@med.auth.gr.
Abstract
BACKGROUND: The incidence of candidemia in pediatric patients follows the same pattern of increase as in adults, but the rate of increase is greater. Pediatric patients in critical condition, particularly young infants, are especially vulnerable to invasive Candida infections (ICI), partly because of their age and severe underlying disease and partly because of the invasive procedures used. DISCUSSION: Central venous catheters and arterial lines, parenteral nutrition, mechanical ventilation and extended use of antimicrobials enhance the risk of ICI. C. albicans continues to be the most prevalent isolate. However, an increasing role of non-C. albicans (NAC) spp., some of which are intrinsically or potentially resistant to antifungal agents, has been observed. NAC spp., particularly C. parapsilosis and C. tropicalis, account for almost half of ICI. The increased use of antifungals in immunocompromised patients, mainly prophylactically, is considered the strongest contributory factor to the changes in species distribution, which have subsequently affected the mortality and choice of empirical treatment. CONCLUSIONS: Prompt removal of lines and initiation of antifungal treatment are the milestones of management. Conventional amphotericin B remains a commonly used antifungal agent, but its lipid formulations and fluconazole are also used frequently. Novel antifungal agents such as second-generation triazoles and echinocandins exhibit potential as alternative agents in critically ill children with ICI. Although response rates are still far from satisfactory, improved understanding of risk factors, preventive strategies and new treatment options promise a better future outcome.
BACKGROUND: The incidence of candidemia in pediatric patients follows the same pattern of increase as in adults, but the rate of increase is greater. Pediatric patients in critical condition, particularly young infants, are especially vulnerable to invasive Candida infections (ICI), partly because of their age and severe underlying disease and partly because of the invasive procedures used. DISCUSSION: Central venous catheters and arterial lines, parenteral nutrition, mechanical ventilation and extended use of antimicrobials enhance the risk of ICI. C. albicans continues to be the most prevalent isolate. However, an increasing role of non-C. albicans (NAC) spp., some of which are intrinsically or potentially resistant to antifungal agents, has been observed. NAC spp., particularly C. parapsilosis and C. tropicalis, account for almost half of ICI. The increased use of antifungals in immunocompromised patients, mainly prophylactically, is considered the strongest contributory factor to the changes in species distribution, which have subsequently affected the mortality and choice of empirical treatment. CONCLUSIONS: Prompt removal of lines and initiation of antifungal treatment are the milestones of management. Conventional amphotericin B remains a commonly used antifungal agent, but its lipid formulations and fluconazole are also used frequently. Novel antifungal agents such as second-generation triazoles and echinocandins exhibit potential as alternative agents in critically ill children with ICI. Although response rates are still far from satisfactory, improved understanding of risk factors, preventive strategies and new treatment options promise a better future outcome.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: L A Waggoner-Fountain; M W Walker; R J Hollis; M A Pfaller; J E Ferguson; R P Wenzel; L G Donowitz Journal: Clin Infect Dis Date: 1996-05 Impact factor: 9.079
Authors: Daniel Kelly Benjamin; William C Miller; Sherry Bayliff; Lisa Martel; Kenneth A Alexander; Paul Langlie Martin Journal: Pediatr Infect Dis J Date: 2002-03 Impact factor: 2.129
Authors: M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu Journal: Am J Med Date: 1996-06 Impact factor: 4.965
Authors: Galit P Rosen; Karin Nielsen; Sungching Glenn; Jon Abelson; Jaime Deville; Theodore B Moore Journal: J Pediatr Hematol Oncol Date: 2005-03 Impact factor: 1.289
Authors: Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes Journal: Clin Infect Dis Date: 2003-08-14 Impact factor: 9.079
Authors: A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou Journal: Mycopathologia Date: 2011-11-11 Impact factor: 2.574
Authors: Mary Ann Jabra-Rizk; Eric F Kong; Christina Tsui; M Hong Nguyen; Cornelius J Clancy; Paul L Fidel; Mairi Noverr Journal: Infect Immun Date: 2016-09-19 Impact factor: 3.441
Authors: L Vogiatzi; S Ilia; G Sideri; E Vagelakoudi; M Vassilopoulou; M Sdougka; G Briassoulis; I Papadatos; P Kalabalikis; L Sianidou; E Roilides Journal: Intensive Care Med Date: 2013-08-14 Impact factor: 17.440